Chongqing Pharscin Pharmaceutical Co Ltd Asset Resilience Ratio
Chongqing Pharscin Pharmaceutical Co Ltd asset resilience ratio. Chongqing Pharscin Pharmaceutical Co Ltd (002907) has an Asset Resilience Ratio of 14.54% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See how many days can Chongqing Pharscin Pharmaceutical Co Ltd fund operations to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Chongqing Pharscin Pharmaceutical Co Ltd (2017–2024)
Asset resilience ratio of Chongqing Pharscin Pharmaceutical Co Ltd from 2017 to 2024. This chart shows how Chongqing Pharscin Pharmaceutical Co Ltd's Asset Resilience Ratio has changed over time. Read 002907 total debt and obligations for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Chongqing Pharscin Pharmaceutical Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Chongqing Pharscin Pharmaceutical Co Ltd total assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥290.43 Million | 14.54% |
| Total Liquid Assets | CN¥290.43 Million | 14.54% |
Asset Resilience Insights
- Moderate Liquidity: Chongqing Pharscin Pharmaceutical Co Ltd has 14.54% of assets in liquid form.
- While adequate for normal operations, this level may limit flexibility during economic stress.
- The company has significant short-term investments, indicating active treasury management.
Chongqing Pharscin Pharmaceutical Co Ltd Industry Peers by Asset Resilience Ratio
Compare Chongqing Pharscin Pharmaceutical Co Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Jiangsu Hengrui Medicine Co Ltd
SHG:600276 |
Drug Manufacturers - Specialty & Generic | 0.16% |
|
Sandoz Group AG
SW:SDZ |
Drug Manufacturers - Specialty & Generic | 7.89% |
|
H Lundbeck A/S
CO:HLUN-B |
Drug Manufacturers - Specialty & Generic | -0.56% |
|
Changchun High & New Technology Industries Group Inc
SHE:000661 |
Drug Manufacturers - Specialty & Generic | 5.50% |
|
Hubei Jumpcan Pharmaceutical Co Ltd
SHG:600566 |
Drug Manufacturers - Specialty & Generic | 47.16% |
|
Kangmei Pharmaceutical Co Ltd
SHG:600518 |
Drug Manufacturers - Specialty & Generic | 0.00% |
|
Viyash Scientific Limited
NSE:SEQUENT |
Drug Manufacturers - Specialty & Generic | 0.08% |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153 |
Drug Manufacturers - Specialty & Generic | 1.81% |
Chongqing Pharscin Pharmaceutical Co Ltd Asset Resilience Ratio by Year (2017–2024)
Chongqing Pharscin Pharmaceutical Co Ltd asset resilience ratio by year from 2017 to 2024. The table below shows the annual Asset Resilience Ratio data for Chongqing Pharscin Pharmaceutical Co Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 6.29% | CN¥120.61 Million ≈ $17.65 Million |
CN¥1.92 Billion ≈ $280.60 Million |
+10.63pp |
| 2023-12-31 | -4.34% | CN¥-80.31 Million ≈ $-11.75 Million |
CN¥1.85 Billion ≈ $270.93 Million |
-3.32pp |
| 2022-12-31 | -1.02% | CN¥-18.97 Million ≈ $-2.78 Million |
CN¥1.87 Billion ≈ $273.15 Million |
-5.57pp |
| 2021-12-31 | 4.55% | CN¥80.61 Million ≈ $11.80 Million |
CN¥1.77 Billion ≈ $259.22 Million |
+1.64pp |
| 2020-12-31 | 2.91% | CN¥50.07 Million ≈ $7.33 Million |
CN¥1.72 Billion ≈ $251.90 Million |
-8.89pp |
| 2019-12-31 | 11.80% | CN¥193.25 Million ≈ $28.28 Million |
CN¥1.64 Billion ≈ $239.61 Million |
-8.08pp |
| 2017-12-31 | 19.88% | CN¥176.00 Million ≈ $25.75 Million |
CN¥885.15 Million ≈ $129.52 Million |
-- |
About Chongqing Pharscin Pharmaceutical Co Ltd
Chongqing Pharscin Pharmaceutical Co., Ltd. engages in the research and development, production, and sale of drugs in China. The company offers tablets, powders, granules, soft capsules, powder injections, freeze-dried powders, injections, chemical raw materials, and small volume injections. It provides its products for the treatment of CNS, digestion, otolaryngology, oncology, cardiovascular, an… Read more